Stacy Ku
Stock Analyst at TD Cowen
(4.28)
# 1,335
Out of 4,429 analysts
152
Total ratings
54.4%
Success rate
11.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Maintained: Buy | n/a | $14.70 | - | 4 | Jun 11, 2026 | |
| SLGL Sol-Gel Technologies | Initiated Coverage: Buy | n/a | $74.46 | - | 1 | May 29, 2026 | |
| TARA Protara Therapeutics | Rated: Buy | n/a | $3.98 | - | 14 | May 20, 2026 | |
| VRCA Verrica Pharmaceuticals | Maintained: Buy | $20 | $5.63 | +255.24% | 14 | May 12, 2026 | |
| TNXP Tonix Pharmaceuticals Holding | Maintained: Buy | $22 | $12.01 | +83.18% | 2 | May 11, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | $60 | $6.15 | +875.61% | 17 | May 11, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Buy | $17 | $16.46 | +3.28% | 13 | May 7, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Buy | $30 | $8.99 | +233.70% | 16 | May 6, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $65 | $44.38 | +46.46% | 20 | May 5, 2026 | |
| GRCE Grace Therapeutics | Rated: Buy | $12 → $8 | $2.38 | +236.13% | 2 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €310.00 | $250.32 | +23.84% | 22 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $165 → $175 | $143.13 | +22.27% | 6 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $40.02 | - | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.6354 | +214.76% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $5.85 | - | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $19.21 | n/a | 1 | Feb 26, 2025 |
Avalo Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $14.70
Upside: -
Sol-Gel Technologies
May 29, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $74.46
Upside: -
Protara Therapeutics
May 20, 2026
Rated: Buy
Price Target: n/a
Current: $3.98
Upside: -
Verrica Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $20
Current: $5.63
Upside: +255.24%
Tonix Pharmaceuticals Holding
May 11, 2026
Maintained: Buy
Price Target: $22
Current: $12.01
Upside: +83.18%
LENZ Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $6.15
Upside: +875.61%
Aurinia Pharmaceuticals
May 7, 2026
Maintained: Buy
Price Target: $17
Current: $16.46
Upside: +3.28%
BioCryst Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $30
Current: $8.99
Upside: +233.70%
Supernus Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $65
Current: $44.38
Upside: +46.46%
Grace Therapeutics
Apr 23, 2026
Rated: Buy
Price Target: $12 → $8
Current: $2.38
Upside: +236.13%
Mar 19, 2026
Reiterated: Buy
Price Target: €310.00
Current: $250.32
Upside: +23.84%
Mar 13, 2026
Maintained: Buy
Price Target: $165 → $175
Current: $143.13
Upside: +22.27%
Nov 12, 2025
Maintained: Buy
Price Target: n/a
Current: $40.02
Upside: -
Nov 7, 2025
Maintained: Buy
Price Target: $2
Current: $0.6354
Upside: +214.76%
Oct 30, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $5.85
Upside: -
Feb 26, 2025
Maintained: Buy
Price Target: n/a
Current: $19.21
Upside: n/a